Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Vanda Pharmaceuticals (VNDA) Tops Q3 EPS by 16c
November 7, 2018 4:52 PM ESTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q3 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $49.14 million versus the consensus estimate of $49.44 million.
GUIDANCE:
Vanda reiterates 2018 net product sales guidance of $180 million to $200 million.
For... More
